EBCTCG (Early Breast Cancer Trialists’ Collaborative Group); McGale, P.; Taylor, C.; Correa, C.; Cutter, D.; Duane, F.; Ewertz, M.; Gray, R.; Mannu, G.; Peto, R.; et al. Effect of Radiotherapy after Mastectomy and Axillary Surgery on 10-Year Recurrence and 20-Year Breast Cancer Mortality: Meta-Analysis of Individual Patient Data for 8135 Women in 22 Randomised Trials. Lancet 2014, 383, 2127–2135, https://doi.org/10.1016/S0140-6736(14)60488-8.

Effect of Radiotherapy after Breast-Conserving Surgery on 10-Year Recurrence and 15-Year Breast Cancer Death: Meta-Analysis of Individual Patient Data for 10 801 Women in 17 Randomised Trials. Lancet 2011, 378, 1707–1716, https://doi.org/10.1016/S0140-6736(11)61629-2.

Schmid P, Cortes J, Dent R, Pusztai L, McArthur H, Kümmel S, Bergh J, Denkert C, Park YH, Hui R et al (2022) Event-Free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer. N Engl J Med 386:556–567. https://doi.org/10.1056/NEJMoa2112651

Article  CAS  PubMed  Google Scholar 

Zhao Y, Liu L, Weng L (2021) Comparisons of Underlying Mechanisms, Clinical Efficacy and Safety Between Anti-PD‑1 and Anti-PD-L1 Immunotherapy: The State-of-the-Art Review and Future Perspectives. Front Pharmacol 12:

Xu, C.; Jin, J.-Y.; Zhang, M.; Liu, A.; Wang, J.; Mohan, R.; Kong, F. (Spring); Lin, S.H. The Impact of the Effective Dose to Immune Cells on Lymphopenia and Survival of Esophageal Cancer after Chemoradiotherapy. Radiother Oncol 2020, 146, 180–186, https://doi.org/10.1016/j.radonc.2020.02.015.

Yu Y, Fu P, Jin J‑Y, Gao S, Wang W, Machtay M, Wang L, Kong F‑MS, Yu J (2021) Impact of Effective Dose to Immune Cells (EDIC) on Lymphocyte Nadir and Survival in Limited-Stage SCLC. Radiother Oncol 162:26–33. https://doi.org/10.1016/j.radonc.2021.06.020

Article  PubMed  Google Scholar 

Jin J‑Y, Hu C, Xiao Y, Zhang H, Paulus R, Ellsworth SG, Schild SE, Bogart JA, Dobelbower MC, Kavadi VS et al (2021) Higher Radiation Dose to the Immune Cells Correlates with Worse Tumor Control and Overall Survival in Patients with Stage III NSCLC: A Secondary Analysis of RTOG0617. Cancers (basel) 13:6193. https://doi.org/10.3390/cancers13246193

Article  PubMed  Google Scholar 

Zolcsak Z, Loap P, Fourquet A, Kirova YM (2022) Long-Term Follow-up Results of Intensity-Modulated Radiotherapy with Helicoïdal Tomotherapy for Non-Metastatic Breast Cancers: Single Centre Experience. Cancer Radiother 26:654–662. https://doi.org/10.1016/j.canrad.2021.12.002

Article  CAS  PubMed  Google Scholar 

Vescovi JD, Zimmerman SL, Miller WC, Hildebrandt L, Hammer RL, Fernhall B (2001) Evaluation of the BOD POD for Estimating Percentage Body Fat in a Heterogeneous Group of Adult Humans. Eur J Appl Physiol 85:326–332. https://doi.org/10.1007/s004210100459

Article  CAS  PubMed  Google Scholar 

Aboudaram A, Loap P, Loirat D, Dhia SB, Cao K, Fourquet A, Kirova Y (2021) Pertuzumab and Trastuzumab Combination with Concomitant Locoregional Radiotherapy for the Treatment of Breast Cancers with HER2 Receptor Overexpression. Cancers (basel) 13:4790. https://doi.org/10.3390/cancers13194790

Article  CAS  PubMed  Google Scholar 

Quintin K, Loap P, Fourquet A, Kirova Y (2023) Late Hepatic Toxicity after Breast Cancer Intensity-Modulated Radiotherapy Using Helicoidal Tomotherapy. Cancer Radiother 27:267–272. https://doi.org/10.1016/j.canrad.2023.03.001

Article  CAS  PubMed  Google Scholar 

Loap P, Vu-Bezin J, Monceau V, Jacob S, Fourquet A, Kirova Y (2023) Dosimetric Evaluation of the Benefit of Deep Inspiration Breath Hold (DIBH) for Locoregional Irradiation of Right Breast Cancer with Volumetric Modulated Arctherapy (VMAT). Acta Oncol 62:150–158. https://doi.org/10.1080/0284186X.2023.2177976

Article  PubMed  Google Scholar 

Fleming J, Conway J, Majoral C, Bennett M, Caillibotte G, Montesantos S, Katz I (2014) Determination of Regional Lung Air Volume Distribution at Mid-Tidal Breathing from Computed Tomography: A Retrospective Study of Normal Variability and Reproducibility. BMC Med Imaging 14:25. https://doi.org/10.1186/1471-2342-14-25

Article  PubMed  PubMed Central  Google Scholar 

Kundrát P, Rennau H, Remmele J, Sebb S, Simonetto C, Kaiser JC, Hildebrandt G, Wolf U, Eidemüller M (2022) Anatomy-Dependent Lung Doses from 3D-Conformal Breast-Cancer Radiotherapy. Sci Rep 12:10909. https://doi.org/10.1038/s41598-022-14149-2

Article  CAS  PubMed  PubMed Central  Google Scholar 

Loap P, Kirova Y (2020) Evaluating Cardiac Substructure Exposure in Breast Rotational Intensity Modulated Radiation Therapy: Effects of Cancer Laterality, Fractionation and Deep Inspiration Breath-Hold. Cancer Radiother

Pan H, Gray R, Braybrooke J, Davies C, Taylor C, McGale P, Peto R, Pritchard KI, Bergh J, Dowsett M et al (2017) 20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years. N Engl J Med 377:1836–1846. https://doi.org/10.1056/NEJMoa1701830

Article  PubMed  PubMed Central  Google Scholar 

Loap P, Kirov K, Kirova Y (2020) Cardiotoxicity in Breast Cancer Patients Treated with Radiation Therapy: From Evidences to Controversies. Crit Rev Oncol Hematol 156:103121. https://doi.org/10.1016/j.critrevonc.2020.103121

Article  PubMed  Google Scholar 

Errahmani MY, Locquet M, Spoor D, Jimenez G, Camilleri J, Bernier M‑O, Broggio D, Monceau V, Ferrières J, Thariat J et al (2022) Association Between Cardiac Radiation Exposure and the Risk of Arrhythmia in Breast Cancer Patients Treated With Radiotherapy: A Case-Control Study. Front Oncol 12:892882. https://doi.org/10.3389/fonc.2022.892882

Article  PubMed  PubMed Central  Google Scholar 

Errahmani, M.Y.; Locquet, M.; Broggio, D.; Spoor, D.; Jimenez, G.; Camilleri, J.; Langendijk, J.A.; Crijns, A.P.G.; Bernier, M.O.; Ferrières, J.; et al. Supraventricular Cardiac Conduction System Exposure in Breast Cancer Patients Treated with Radiotherapy and Association with Heart and Cardiac Chambers Doses. Clin Transl Radiat Oncol 2022, 38, 62–70, https://doi.org/10.1016/j.ctro.2022.10.015.

Loap P, Tkatchenko N, Goudjil F, Ribeiro M, Baron B, Fourquet A, Kirova Y (2021) Cardiac Substructure Exposure in Breast Radiotherapy: A Comparison between Intensity Modulated Proton Therapy and Volumetric Modulated Arc Therapy. Acta Oncol. https://doi.org/10.1080/0284186X.2021.1907860

Article  PubMed  Google Scholar 

Loap P, Beddok A, Cao KI, Goudjil F, Fourquet A, Dendale R, Kirova Y (2021) Clinical Practice of Breast Cancer Protontherapy: A Single-Centre Experience from Selection to Treatment. Cancer Radiother. https://doi.org/10.1016/j.canrad.2021.01.005

Article  PubMed  Google Scholar 

Loap P, De Marzi L, Almeida CE, Barcellini A, Bradley J, de Santis MC, Dendale R, Jimenez R, Orlandi E, Kirova Y (2022) Hadrontherapy Techniques for Breast Cancer. Crit Rev Oncol Hematol 169:103574. https://doi.org/10.1016/j.critrevonc.2021.103574

Article  PubMed  Google Scholar 

Bekelman JE, Lu H, Pugh S, Baker K, Berg CD, de Gonzalez AB, Braunstein LZ, Bosch W, Chauhan C, Ellenberg S et al (2019) Pragmatic Randomised Clinical Trial of Proton versus Photon Therapy for Patients with Non-Metastatic Breast Cancer: The Radiotherapy Comparative Effectiveness (RadComp) Consortium Trial Protocol. Bmj Open 9:e25556. https://doi.org/10.1136/bmjopen-2018-025556

Article  PubMed  PubMed Central  Google Scholar 

Stick LB, Lorenzen EL, Yates ES, Anandadas C, Andersen K, Aristei C, Byrne O, Hol S, Jensen I, Kirby AM et al (2021) Selection Criteria for Early Breast Cancer Patients in the DBCG Proton Trial—The Randomised Phase III Trial Strategy. Clin Transl Radiat Oncol 27:126–131. https://doi.org/10.1016/j.ctro.2021.01.012

Article  CAS  PubMed  PubMed Central  Google Scholar 

Friedes C, Iocolano M, Lee SH, Duan L, Li B, Doucette A, Cohen RB, Aggarwal C, Sun LL, Levin WP et al (2024) The Effective Radiation Dose to Immune Cells Predicts Lymphopenia and Inferior Cancer Control in Locally Advanced NSCLC. Radiother Oncol 190:110030. https://doi.org/10.1016/j.radonc.2023.110030

Article  CAS  PubMed  Google Scholar